Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

UniCar Closes C Funding for “Safe” CAR-T Dual Target Candidate

publication date: Aug 29, 2022

Shanghai UniCar Therapy closed a Series C financing to advance clinical trials of its ssCART-19 injection in patients with leukemia. Guan Bang Fund and Junci Investment were the two named investors in the C round. UniCar’s ssCART-19 injection, the company’s lead CAR-T 2.0, expresses single-chain antibodies targeting CD19 and IL-6 silencing elements (shRNA). The company expects IL-6 silencing will decrease cytokine release syndrome in patients. UniCar focuses on refining CAR-T products to increase their efficacy. The company said the C round raised “tens of millions of RMB.” More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital